Site Newsletter

Press Release

NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting a Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clinical Activity of the NANT Cancer Vaccine

NantKwest (NASDAQ: NK), a pioneering, next generation, clinical-stage
immunotherapy company focused on harnessing the unique power of the
human immune system using natural killer (NK) cells to treat cancer,
announced today that the company will be hosting an Investor/Analyst Day
on Tuesday, January 9th in San Francisco, California.

NantKwest will be sharing with analysts and investors a review of the
company’s activities in 2017 and provide a detailed overview for 2018.
The record number of 15 INDs authorized in 2017 (aNK, haNK,
Cryopreserved haNK and taNK) will be announced, detailing the multiple
tumor types to be studied with combination chemo-radiation therapy and
activators of adaptive immune system through adenovirus, yeast and super
agonist IL-15 platforms. In addition, details will be presented
regarding authorization in Europe to treat patients with glioblastoma
and authorization by the FDA to initiate high-affinity natural killer
(haNK) cell trials in cancer patients with HIV.

First in-human clinical data will be revealed including safety and early
signs of clinical activity in patients receiving freshly cultured haNK,
cryopreserved haNK and combinations of NK cells (aNK and haNK) with
adenovirus, yeast, and super agonist IL-15 platforms. These studies form
the basis for multiple Phase II and registration trials anticipated to
be initiated in 2018.

At this event, senior management of NantKwest will provide a review of
its ongoing R&D program, as well as provide an in-depth clinical trial
roadmap for the company’s clinical programs for 2018 and the current
status of the GMP manufacturing plants.

A webcast of the event will begin at 7:00 PM PT on Tuesday, January 9,
2018 and is expected to conclude at 9:00 PT. A link to the live webcast
can be accessed by visiting the Investors page of the company’s website.
In addition, a replay of the event will be posted on the website after
the event and will be available for 30 days following the event.

About NantKwest

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage
immunotherapy company focused on harnessing the unique power of our
immune system using natural killer (NK) cells to treat cancer,
infectious diseases and inflammatory diseases. NK cells are the body’s
first line of defense due to the innate ability of NK cells to rapidly
identify and destroy cells under stress, such as cancer or
virally-infected cells.

NantKwest’s unique NK cell-based platform, with the capacity to grow
active killer cells as a biological cancer therapy, has been designed to
induce cell death against cancer or infected cells by three different
modes of action: (1) Direct killing using activated NK cells (aNK) that
release toxic granules directly into the cell through cell to cell
contact, (2) Antibody-mediated killing using haNKs, which are NK cells
engineered to incorporate a high affinity receptor that binds to an
administered antibody, enhancing the cancer cell killing effect of that
antibody, and (3) Targeted activated killing using taNKs, which are NK
cells engineered to incorporate chimeric antigen receptors (CARs) to
target tumor-specific antigens found on the surface of cancer cells.

Our aNK, haNK and taNK platform addresses certain limitations of T cell
therapies including the reduction of risk of serious “cytokine storms”
reported after T cell therapy. As an “off-the-shelf” therapy,
NantKwest’s NK cells do not rely on a patient’s own often compromised
immune system. In Phase 1 clinical trials in patients with late stage
cancer, NantKwest’s NK cells have been successfully administered as an
outpatient infusion therapy without any reported severe side effects,
even at doses of 10 billion cells.

By leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs that include a Phase 2 trial
for a rare form of melanoma and the planned initiation of a clinical
trial of NK cells targeted to breast cancer, we believe NantKwest is
uniquely positioned to be the premier immunotherapy company and
transform medicine by delivering living drugs in a bag and bringing
novel NK cell-based therapies to routine clinical care. For more
information, please visit www.nantkwest.com.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.